Nitisinone: a review

References

• Michaeley WJ, Kratz GW. Certain 2-(2-substituted benzyl)-1,3-cyclohexanediones. European Patent Application 0135191. 1986.
   Google Scholar
• Prisbylla MP, Onisko BC, Shribbs JM, et al. The novel mechanism of action of the herbicidal triketones. In: Proceedings of the Brighton Crop Protection Conference-Weeds, London, UK. 1993;2:731–738.
   Google Scholar
• Lock EA, Ellis MK, Gaskin P, et al. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis. 1998;21(5):498–506.
   PubMed Web of Science ®Google Scholar
• Schulz A, Ort O, Beyer P, Kleinig H. SC-0051, a 2-benzoyl-cyclohexane-1,3-dione bleaching herbicide, is a potent inhibitor of the enzyme p-hydroxyphenylpyruvate dioxygenase. FEBS Lett. 1993;318(2):162–166.
   Web of Science ®Google Scholar
• Kavana M, Moran GR. Interaction of (4-hydroxyphenyl) pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. Biochemistry. 2003;42(34):10238–10245.
   Web of Science ®Google Scholar
• Ellis MK, Whitfield AC, Gowans LA, et al. Inhibition of 4-hydroxy-phenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Toxicol Appl Pharmacol. 1995;133(1):12–19.
   Web of Science ®Google Scholar
• Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340(8823):813–817.
   PubMed Web of Science ®Google Scholar
• Holme E, Lindstedt S. Tyrosinemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis. 1998;21(5):507–517.
   PubMed Web of Science ®Google Scholar
• McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinemia type 1. Drugs. 2006;66(6):743–750.
   Web of Science ®Google Scholar
• Drug to treat rare pediatric liver disease. FDA Consum. 2002;36(2):5.
   Google Scholar
• Santra S, Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008;9(7):1229–1236.
   PubMed Web of Science ®Google Scholar
• Hanauske-Abel HM, Popowicz A, Remotti H, Newfield RS, Levy J. TyrosinemiaI, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism. J Pediatr Gastroenterol Nutr. 2002;35(1):73–78.
   Web of Science ®Google Scholar
• Laschi M, Bernardini G, Dreassi E, et al. Inhibition of para-hydroxyphenylpyruvate dioxygenase by analogues of the herbicide nitisinone as a strategy to decrease homogentisic acid levels, the causative agent of alkaptonuria. Chem Med Chem. 2016;11(7):674678.
   Google Scholar
• Lock EA, Gaskin P, Ellis MK, McLean Provan W, Robinson M, Smith LL. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology. 2000;144(1–3):179–187.
   Web of Science ®Google Scholar
• Hall MG, Wilks MF, Provan WM, Eksborg S, Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol. 2001;52(2):169–177.
   PubMed Web of Science ®Google Scholar
• Schlune A, Thimm E, Herebian D, Spiekerkoetter U. Single dose NTBC-treatment of hereditary tyrosinemia type I. J Inherit Metab Dis. 2012;35(5):831–836.
   Web of Science ®Google Scholar
• Orfadin nitisinone (n.d.). Available from: http://orfadin.com/wp-content/uploads/2016/06/prescribing_information.pdf. Accessed September 3, 2016.
   Google Scholar
• Lock EA, Gaskin P, Ellis MK, et al. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol Appl Pharmacol. 1996;141(2):439–447.
   PubMed Web of Science ®Google Scholar
• Szczeciński P, Lamparska D, Gryff-Keller A, Gradowska W. Identification of 2-[2-nitro-4-(trifluoromethyl)benzoyl]-cyclohexane-1,3-dione metabolites in urine of patients suffering from tyrosinemia type I with the use of 1H and 19F NMR spectroscopy. Acta Biochim Pol. 2008;55(4):749–752.
   Web of Science ®Google Scholar
• Grompe M, Lindstedt S, al-Dhalimy M, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet. 1995;10(4):453–460.
   PubMed Web of Science ®Google Scholar
• Neat JN, Wolff A, K F, et al. In vitro inhibition and induction of human liver cytochrome P450 enzymes by NTBC and its metabolism in human liver microsomes. Drug Metab Rev. 2010;42(Supp 1):115–116.
   Google Scholar
• Lock EA, Gaskin P, Ellis M, Provan WM, Smith LL. Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury. Toxicol Appl Pharmacol. 2006;215(1):9–16.
   PubMed Web of Science ®Google Scholar
• Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008;31(1):81–87.
   PubMed Web of Science ®Google Scholar
• Introne WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab. 2011;103(4):307–314.
   PubMed Web of Science ®Google Scholar
• Olsson B, Cox TF, Psarelli EE, et al. Relationship between serum concentrations of nitisinone and its effect on homogentisic acid and tyrosine in patients with alkaptonuria. JIMD Rep. 2015;24:21–27.
   Google Scholar
• Chakrapani A, Gissen P, McKiernan P. Disorders of tyrosine metabolism. In: Saudubray JM, van den Berghe G, Walter JH, editors. Inborn Metabolic Diseases, 5th ed. Heidelberg: Springer; 2012:265–276.
   Google Scholar
• Sassa S, Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest. 1983;71(3):625–634.
   PubMed Web of Science ®Google Scholar
• Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalties and genomic instability. Hum Mol Genet. 2001;10(17):1741–1752.
   Web of Science ®Google Scholar
• Jonas MM, Perez-Atayde AR. Liver disease in infancy and childhood. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff’s Diseases of Liver, 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:1307–1347.
   Google Scholar
• Bergman AJ, van den Berg IE, Brink W, Poll-The BT, Ploos van Amstel JK, Berger R. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hum Mutat. 1998;12(1):19–26.
   Web of Science ®Google Scholar
• Arranz JA, Piñol F, Kozak L, et al. Splicing mutations, mainly IVS6-1(G≥T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Hum Mutat. 2002;20(3):180–188.
   Web of Science ®Google Scholar
• Dursun A, Ozgül RK, Sivri S, et al. Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease. JIMD Rep. 2011;1:17–21.
   Google Scholar
• Larochelle J, Alvarez F, Bussières JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab. 2012;107(1–2):49–54.
   PubMed Web of Science ®Google Scholar
• Angileri F, Bergeron A, Morrow G, et al. Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1. JIMD Rep. 2015;19:43–58.
   Google Scholar
• van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994;20(5):1187–1191.
   Web of Science ®Google Scholar
• Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol. 2001;4(3):212–221.
   Web of Science ®Google Scholar
• Mitchell G, Russo PA, Dubois J, Alverez F. Tyrosinemia. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver Disease in Children. 3rd ed. New York: Cambridge University Press; 2007:694–713.
   Google Scholar
• Baumann U, Preece MA, Green A, Kelly DA, McKiernan PJ. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis. 2005;28(2):131–135.
   Web of Science ®Google Scholar
• Arora N, Stumper O, Wright J, Kelly DA, Mckiernan P. Cardiomyopathy in tyrosinaemia type 1 is common but usually benign. J Inherit Metab Dis. 2006;29(1):54–57.
   Web of Science ®Google Scholar
• Mohamed S, Kambal MA, Al Jurayyan NA, et al. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy. BMC Res Notes. 2013;6:362.
   Google Scholar
• Squires JE, Heubi JE. Metabolic liver disease: Part 1. In: Murray KF, Simon H, editors. Diseases of the Liver in Children, Evaluation and Management. Heidelberg: Springer; 2013:151–188.
   Google Scholar
• Fernández-Lainez C, Ibarra-González I, Belmont-Martínez L, Monroy-Santoyo S, Guillén-López S, Vela-Amieva M. Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico. Ann Hepatol. 2014;13(2):265–272.
   Web of Science ®Google Scholar
• Simoncelli M, Samson J, Bussières JF, et al. Cost-consequence analysis of nitisinone for treatment of tyrosinemia type I. Can J Hosp Pharm. 2015;68(3):210–217.
   PubMedGoogle Scholar
• McKiernan PJ, Preece MA, Chakrapani A. Outcome of children with hereditary tyrosinaemia following newborn screening. Arch Dis Child. 2015;100(8):738–741.
   Web of Science ®Google Scholar
• de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013;8:8.
   PubMed Web of Science ®Google Scholar
• Mayorandan S, Meyer U, Gokcay G, et al. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis. 2014;9:107.
   PubMed Web of Science ®Google Scholar
• El-Karaksy H, Rashed M, El-Sayed R, et al. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr. 2010;169(6):689–693.
   Web of Science ®Google Scholar
• D’Eufemia P, Celli M, Tetti M, Finocchiaro R. Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended. Eur J Pediatr. 2011;170(6):819.
   Web of Science ®Google Scholar
• Herebian D, Spiekerkötter U, Lamshöft M, Thimm E, Laryea M, Mayatepek E. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(14–15):1453–1459.
   Web of Science ®Google Scholar
• Prieto JA, Andrade F, Lage S, Aldámiz-Echevarría L. Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(11–12):671–676.
   Web of Science ®Google Scholar
• Sander J, Janzen N, Terhardt M et al. Monitoring tyrosinaemia type I: blood spot test for nitisinone (NTBC). Clin Chim Acta. 2011;412(1–2):134–138.
   Web of Science ®Google Scholar
• Bielenstein M, Astner L, Ekberg S. Determination of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in plasma by direct injection into a coupled column liquid chromatographic system. J Chromatogr B Biomed Sci Appl. 1999;730(2):177–182.
   Google Scholar
• Cansever MS, Aktuğlu-Zeybek AC, Erim FB. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis. Talanta. 2010;80(5):1846–1848.
   Web of Science ®Google Scholar
• Barkaoui E, Debray D, Habès D, Ogier H, Bernard O. Évolution favorable sous traitement par NTBC de l’insuffisance hépatique aiguë révélatrice de la tyrosinémie héréditaire de type I [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I]. Arch Pediatr. 1999;6(5):540–544. French.
   Google Scholar
• Joshi SN, Venugopalan P. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation. Ann Trop Paediatr. 2004;24(3):259–265.
   PubMed Web of Science ®Google Scholar
• Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis. 2000;4(4):805–814.
   Google Scholar
• Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr. 1999;158(Suppl 2):S49–S54.
   PubMed Web of Science ®Google Scholar
• El-Karaksy H, Fahmy M, El-Raziky M, et al. Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases. World J Pediatr. 2011;7(3):224–231.
   Web of Science ®Google Scholar
• Luijerink MC, Jacobs SM, van Beurden EA, et al. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol. 2003;39(6):901–909.
   Web of Science ®Google Scholar
• Al-Dhalimy M, Overturf K, Finegold M, Grompe M. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab. 2002;75(1):38–45.
   PubMed Web of Science ®Google Scholar
• Dieter MZ, Freshwater SL, Miller ML, Shertzer HG, Dalton TP, Nebert DW. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress. Free Radic Biol Med. 2003;35(4):351–367.
   PubMed Web of Science ®Google Scholar
• Pitkänen S, Salo MK, Vettenranta K, Näntö-Salonen K, Heikinheimo M. Serum type III procollagen in children with type I herediatry tyrosinemia. J Pediatr Gastroenterol Nutr. 1999;29(1):38–41.
   Web of Science ®Google Scholar
• van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro-methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr. 2005;40(1):90–93.
   PubMed Web of Science ®Google Scholar
• Zeybek AC, Kiykim E, Soyucen E, et al. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int. 2015;57(2):281–289.
   PubMed Web of Science ®Google Scholar
• Pérez-Cerdá C, Merinero B, Sanz P, et al. Liver transplantation in nine Spanish patients with tyrosinaemia type I. J Inherit Metab Dis. 1995;18(2):119–122.
   Web of Science ®Google Scholar
• van Ginkel WG, Gouw AS, van der Jagt EJ, de Jong KP, Verkade HJ, van Spronsen FJ. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP. Pediatrics. 2015;135(3):e749–e752.
   PubMed Web of Science ®Google Scholar
• Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr. 1976;88(3):434–438.
   PubMed Web of Science ®Google Scholar
• McKiernan PJ. Nitisinone for the treatment of hereditary tyrosinemia type I. Expert Opin Orphan Drugs. 2013;1(6):491–497.
   Web of Science ®Google Scholar
• Sun MS, Hattori S, Kubo S, Awata H, Matsuda I, Endo F. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice. J Am Soc Nephrol. 2000;11(2):291–300.
   PubMed Web of Science ®Google Scholar
• Spencer PD, Roth KS. Effects of succinylacetone on amino acid uptake in the rat kidney. Biochem Med Metab Biol. 1987;37(1):101–109.
   Google Scholar
• Forget S, Patriquin HB, Dubois J, et al. The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol. 1999;29(2):104–108.
   Web of Science ®Google Scholar
• Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008;31(3):399–402.
   PubMed Web of Science ®Google Scholar
• Maiorana A, Malamisura M, Emma F, Boenzi S, Di Ciommo VM, Dionisi-Vici C. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1. Mol Genet Metab. 2014;113(3):188–193.
   PubMed Web of Science ®Google Scholar
• Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis. 2005;28(6):871–876.
   PubMed Web of Science ®Google Scholar
• Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis. 2014;37(5):745–752.
   PubMed Web of Science ®Google Scholar
• Gibbs TC, Payan J, Brett EM, Lindstedt S, Holme E, Clayton PT. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase. J Neurol Neurosurg Psychiatry. 1993;56(10):1129–1132.
   PubMed Web of Science ®Google Scholar
• Mitchell G, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med. 1990;322(7):432–437.
   PubMed Web of Science ®Google Scholar
• Schlump JU, Perot C, Ketteler K, et al. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis. 2008;31(Suppl 2):S223–S225.
   Google Scholar
• Önenli Mungan N, Yıldızdaş D, Kör D, et al. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone. Metab Brain Dis. 2016;31(5):1181–1183.
   Web of Science ®Google Scholar
• André N, Roquelaure B, Jubin V, Ovaert C. Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I. J Inherit Metab Dis. 2005;28(1):103–106.
   Web of Science ®Google Scholar
• Fernández-Cañón JM, Granadino B, Beltrán-Valero de Bernabé D, et al. The molecular basis of alkaptonuria. Nat Genet. 1996;14(1):19–24.
   PubMed Web of Science ®Google Scholar
• Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis. 2011;34(6):1127–1136.
   Web of Science ®Google Scholar
• Nemethova M, Radvanszky J, Kadasi L, et al. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on “black bone disease” in Italy. Eur J Hum Genet. 2016;24(1):66–72.
   PubMed Web of Science ®Google Scholar
• Lustberg TJ, Schulman JD, Seegmiller JE. Metabolic fate of homogentisic acid-1–14 C (HGA) in alkaptonuria and effectiveness of ascorbic acid in preventing experimental ochronosis. Arthritis Rheum. 1969;12:678.
   Google Scholar
• Peker E, Yonden Z, Sogut S. From darkening urine to early diagnosis of alkaptonuria. Indian J Dermatol Venereol Leprol. 2008;74(6):700.
   Web of Science ®Google Scholar
• Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002;347(26):2111–2121.
   PubMed Web of Science ®Google Scholar
• Milch RA. Studies of alcaptonuria: mechanisms of swelling of homogentisic acid-collagen preparations. Arthritis Rheum. 1961;4:253–267.
   Google Scholar
• Zannoni VG, Lomtevas N, Goldfinger S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochim Biophys Acta. 1969;177(1):94–105.
   Google Scholar
• Zannoni VG, Malawista SE, La Du BN. Studies on ochronosis. II. Studies on benzoquinoneacetic acid, a probable intermediate in the connective tissue pigmentation of alcaptonuria. Arthritis Rheum. 1962;5:547–556.
   Google Scholar
• Ranganath LR, Cox TF. Natural history of alkaptonuria revisited: analyses based on scoring systems. J Inherit Metab Dis. 2011;34(6):1141–1151.
   PubMed Web of Science ®Google Scholar
• Aquaron R. Alkaptonuria: a very rare metabolic disorder. Indian J Biochem Biophys. 2013;50(5):339–44.
   PubMed Web of Science ®Google Scholar
• Lindner M, Bertelmann T. On the ocular findings in ochronosis: a systemic review of the literature. BMC Opthalmol. 2014;14:12.
   Web of Science ®Google Scholar
• Fisher AA, Davis MW. Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res. 2004;2(4):209–215.
   PubMedGoogle Scholar
• Taylor AM, Wilson PJ, Ingrams DR, Helliwell TR, Gallagher JA, Ranganath LR. Calculi and intracellular ochronosis in the submandibular tissues from a patient with alkaptonuria. J Clin Pathol. 2010;63(2):186–188.
   PubMed Web of Science ®Google Scholar
• Keller JM, Macaulay W, Nercessian OA, Jaffe IA. New developments in ochronosis: review of the literature. Rheumatol Int. 2005;25(2):81–85.
   Web of Science ®Google Scholar
• Manoj Kumar RV, Rajasekaran S. Spontaneous tendon ruptures in alkaptonuria. J Bone Joint Surg Br. 2003;85(6):883–886.
   Google Scholar
• Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab. 2002;77(1–2):136–142.
   Web of Science ®Google Scholar
• Gil JA, Wawrzynski J, Waryasz GR. Orthopedic manifestations of ochronosis: pathophysiology, presentation, diagnosis, and management. Am J Med. 2016;129(5):536.e1–e6.
   Web of Science ®Google Scholar
• Mullan A, Cocker D, Taylor G, Millar C, Ranganath L. Fatal oxidative haemolysis and methaemoglobinaemia in a patient with alkaptonuria and acute kidney injury. Clin Kidney J. 2015;8(1):109–112.
   PubMedGoogle Scholar
• Davison AS, Milan AM, Gallagher JA, Ranganath LR. Acute fatal metabolic complications in alkaptonuria. J Inherit Metab Dis. 2016;39(2):203–210.
   Web of Science ®Google Scholar
• Preston AJ, Keenan CM, Sutherland H, et al. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis. 2014;73(1):284–289.
   PubMed Web of Science ®Google Scholar
• Suwannarat P, O’Brien K, Perry MB, et al. Use of nitisinone in patients with alkaptonuria. Metabolism. 2005;54(6):719–728.
   PubMed Web of Science ®Google Scholar
• Ranganath LR, Milan AM, Hughes AT, et al. Suitability of nitisinone in alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose–response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis. 2016;75(2):362–367.
   PubMed Web of Science ®Google Scholar
• Gertsman I, Barshop BA, Panyard-Davis J, Gangoiti JA, Nyhan WL. Metabolic effects of increasing doses of nitisinone in the treatment of alkaptonuria. JIMD Rep. 2015;24:13–20.
   Google Scholar
• Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St. Jude Children’s Research Hospital experience, 1962 to 1998. J Clin Oncol. 1991;9(9):1599–1608.
   Web of Science ®Google Scholar
• Peinemann F, van Dalen EC, Berthold F. Rapid COJEC induction therapy for high-risk neuroblastoma patients—cochrane review. Klin Padiatr. 2016;228(3):130–134.
   Web of Science ®Google Scholar
• Kobrinsky NL, Sjolander DE. Response of metastatic recurrent neuroblastoma to nitisinone: a modulator of tyrosine metabolism. Pediatr Blood Cancer. 2006;46(4):517–520.
   Web of Science ®Google Scholar
• Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol. 2002;134(2):266–268.
   Web of Science ®Google Scholar
• Gissen P, Preece MA, Willshaw HA, McKiernan PJ. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. J Inherit Metab Dis. 2003;26(1):13–16.
   Web of Science ®Google Scholar
• Gulmez Sevim D, Gumus K, Cavanagh HD. Corneal pseudodendritic lesions masquerading as herpetic keratitis in a patient with tyrosinemia type I. Eye Contact Lens. Epub 2015 Aug 28.
   Google Scholar
• Schauwvlieghe PP, Jaeken J, Kestelyn P, Claerhout I. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC. Cornea. 2013;32(1):91–94.
   Web of Science ®Google Scholar
• Stewart RM, Briggs MC, Jarvis JC, Gallagher JA, Ranganath L. Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report. JIMD Rep. 2014;17:1–6.
   PubMedGoogle Scholar
• Thimm E, Herebian D, Assmann B, Klee D, Mayatepek E, Spiekerkoetter U. Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. Mol Genet Metab. 2011;102(2):122–125.
   PubMed Web of Science ®Google Scholar
• European Public Assessment Report for Orfadin, European Medicines Agency (EMEA) 2005, Scientific Report Doc. Ref. EMA/823169/2009/EMA/H/C/555: Available from: http://www.eespof.gr/sites/default/files/Orfadin-ENG.pdf. Accessed September 15, 2016.
   Google Scholar
• Bendadi F, de Koning TJ, Visser G, et al. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone. J Pediatr. 2014;164(2):398–401.
   PubMed Web of Science ®Google Scholar
• Thimm E, Richter-Werkle R, Kamp G, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis. 2012;35(2):263–268.
   PubMed Web of Science ®Google Scholar
• Pohorecka M, Biernacka M, Jakubowska-Winecka A, et al. Behavioral and intellectual functioning in patients with tyrosinemia type I. Pediatr Endocrinol Diabetes Metab. 2012;18(3):96–100.
   Google Scholar
• Vanclooster A, Devlieger R, Meersseman W, et al. Pregnancy during nitisinone treatment for tyrosinaemia type I: first human experience. JIMD Rep. 2012;5:27–33.
   Google Scholar
• Garcia Segarra N, Roche S, Imbard A, et al. Maternal and fetal tyrosinemia type I. J Inherit Metab Dis. 2010;33(Suppl 3):S507–S510.
   Google Scholar
• Kassel R, Sprietsma L, Rudnick DA. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I. J Pediatr Gastroenterol Nutr. 2015;60(1):e5–e7.
   Web of Science ®Google Scholar